InMed Pharmaceuticals is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in healthy volunteers for INM-755 CBN cream, its lead program in epidermolysis bullosa (EB). CBN is also the active pharmaceutical ingredient in InMed’s second program in glaucoma. In this video, InMed CEO Eric A. Adams talks about CBN’s distinct structural properties and its potential in treatments for skin and ocular diseases.
InMed presents Phase 2 clinical study results at 12th World Congress on Itch
At the 12th World Congress on Itch (WCI), held in Miami on November 5-7, 2023, InMed’s Senior VP, Clinical and Regulatory Affairs, Alexandra Mancini presented